OA11078A - Sulfamide-metalloprotease inhibitors - Google Patents

Sulfamide-metalloprotease inhibitors Download PDF

Info

Publication number
OA11078A
OA11078A OA9900162A OA9900162A OA11078A OA 11078 A OA11078 A OA 11078A OA 9900162 A OA9900162 A OA 9900162A OA 9900162 A OA9900162 A OA 9900162A OA 11078 A OA11078 A OA 11078A
Authority
OA
OAPI
Prior art keywords
alkyl
hydrogen
compound according
aryl
aralkyl
Prior art date
Application number
OA9900162A
Other languages
English (en)
Inventor
Chris Allen Broka
Jeffrey Allen Campbell
Jian Jeffrey Chen
Arlindo Lucas Castel-Hano
Robert Than Hendricks
Michael Joseph Melnick
Keith Adrian Murray Walker
Original Assignee
Hoffmann La Roche
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26713422&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Agouron Pharma filed Critical Hoffmann La Roche
Publication of OA11078A publication Critical patent/OA11078A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA9900162A 1997-01-23 1999-07-23 Sulfamide-metalloprotease inhibitors OA11078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3671497P 1997-01-23 1997-01-23
US6220997P 1997-10-16 1997-10-16

Publications (1)

Publication Number Publication Date
OA11078A true OA11078A (en) 2003-03-17

Family

ID=26713422

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900162A OA11078A (en) 1997-01-23 1999-07-23 Sulfamide-metalloprotease inhibitors

Country Status (35)

Country Link
EP (1) EP0958287B2 (de)
JP (1) JP3563411B2 (de)
KR (1) KR100377696B1 (de)
CN (1) CN1093125C (de)
AR (1) AR011425A1 (de)
AT (1) ATE223909T1 (de)
AU (1) AU730127B2 (de)
BG (1) BG103586A (de)
BR (1) BR9807508A (de)
CA (1) CA2278694C (de)
DE (2) DE69807845T2 (de)
DK (1) DK0958287T3 (de)
EA (1) EA002810B1 (de)
ES (2) ES2183331T3 (de)
FR (1) FR2758559A1 (de)
GB (1) GB2321641B (de)
HR (1) HRP980036A2 (de)
HU (1) HUP0000941A3 (de)
ID (1) ID22849A (de)
IL (1) IL130802A0 (de)
IS (1) IS5125A (de)
IT (1) IT1298163B1 (de)
MA (1) MA26467A1 (de)
NO (1) NO313635B1 (de)
NZ (1) NZ336625A (de)
OA (1) OA11078A (de)
PA (1) PA8445301A1 (de)
PE (1) PE57399A1 (de)
PL (1) PL334846A1 (de)
PT (1) PT958287E (de)
TN (1) TNSN98012A1 (de)
TR (1) TR199901765T2 (de)
UY (1) UY24854A1 (de)
WO (1) WO1998032748A1 (de)
YU (1) YU34599A (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
US6916817B1 (en) 1999-06-04 2005-07-12 Astrazeneca Ab Inhibitors of metalloproteinases
DE60008548T2 (de) * 1999-08-18 2004-08-05 Warner-Lambert Co. Llc Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
WO2001062750A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
RU2283306C2 (ru) 2000-02-21 2006-09-10 Астразенека Аб Пиперидин- и пиперазинзамещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ
US6495358B1 (en) * 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
WO2001083431A1 (fr) * 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Inhibiteurs de mmp-12
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
ATE399012T1 (de) * 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7629341B2 (en) * 2002-06-12 2009-12-08 Symphony Evolution, Inc. Human ADAM-10 inhibitors
EP1493445A1 (de) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibierung von Stress-induzierter Liganden-abhängiger EGFR Aktivierung
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
BRPI0510137A (pt) * 2004-05-19 2007-10-02 Solvay Pharm Gmbh medicamentos contendo n-sulfamoil-n'-arilpiperazinas para a profilaxia ou tratamento da obesidade e condições relacionadas
JP5043668B2 (ja) * 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
DE102004060229A1 (de) 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
JPWO2007102392A1 (ja) * 2006-03-03 2009-07-23 塩野義製薬株式会社 Ｍｍｐ−１３選択的阻害剤
JPWO2008053913A1 (ja) * 2006-11-02 2010-02-25 塩野義製薬株式会社 Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
WO2009050120A1 (de) 2007-10-12 2009-04-23 Basf Se Verfahren zur herstelung von sulfonsäurediamiden
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
ES2736200T3 (es) * 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
KR101913619B1 (ko) * 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
NZ736015A (en) 2015-05-22 2019-04-26 Chong Kun Dang Pharmaceutical Corp Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617318A5 (en) † 1975-09-30 1980-05-30 Ciba Geigy Ag Microbicidal composition.
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
RU2140411C1 (ru) † 1994-05-04 1999-10-27 Новартис Аг Амиды n-сульфонил- и n-сульфиниламинокислот в качестве микробицидов
DE19507447A1 (de) † 1995-03-03 1996-09-05 Vitronic Dr Ing Stein Bildvera Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC
DK0861236T4 (da) * 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
HUP0000941A2 (hu) 2001-04-28
FR2758559A1 (fr) 1998-07-24
GB2321641A (en) 1998-08-05
ES2183331T3 (es) 2003-03-16
CN1093125C (zh) 2002-10-23
ID22849A (id) 1999-12-09
AU730127B2 (en) 2001-02-22
KR20000070398A (ko) 2000-11-25
ATE223909T1 (de) 2002-09-15
GB9801393D0 (en) 1998-03-18
DK0958287T3 (da) 2003-01-20
NZ336625A (en) 2001-04-27
EA199900643A1 (ru) 2000-04-24
PA8445301A1 (es) 2001-07-31
ES2136037A1 (es) 1999-11-01
ITMI980091A1 (it) 1999-07-20
UY24854A1 (es) 2000-12-29
AU6614098A (en) 1998-08-18
CN1250445A (zh) 2000-04-12
EP0958287A1 (de) 1999-11-24
YU34599A (sh) 2002-03-18
PT958287E (pt) 2002-12-31
IL130802A0 (en) 2001-01-28
CA2278694C (en) 2006-09-26
IS5125A (is) 1999-07-22
AR011425A1 (es) 2000-08-16
PL334846A1 (en) 2000-03-27
DE19802350A1 (de) 1998-07-30
TNSN98012A1 (fr) 2005-03-15
BR9807508A (pt) 2000-03-21
BG103586A (bg) 2000-03-31
KR100377696B1 (ko) 2003-03-29
NO993587D0 (no) 1999-07-22
HUP0000941A3 (en) 2002-06-28
EP0958287B2 (de) 2008-04-09
NO993587L (no) 1999-09-22
NO313635B1 (no) 2002-11-04
HRP980036A2 (en) 1998-12-31
WO1998032748A1 (en) 1998-07-30
IT1298163B1 (it) 1999-12-20
MA26467A1 (fr) 2004-12-20
JP2001523222A (ja) 2001-11-20
DE69807845D1 (de) 2002-10-17
CA2278694A1 (en) 1998-07-30
PE57399A1 (es) 1999-06-25
ES2136037B1 (es) 2000-11-16
DE69807845T2 (de) 2003-06-05
EA002810B1 (ru) 2002-10-31
EP0958287B1 (de) 2002-09-11
TR199901765T2 (xx) 1999-10-21
JP3563411B2 (ja) 2004-09-08
GB2321641B (en) 2001-04-04

Similar Documents

Publication Publication Date Title
US5998412A (en) Sulfamide-metalloprotease inhibitors
EP0958287B1 (de) Sulfamide-metalloprotease inhibitoren
US6376506B1 (en) Sulfamide-metalloprotease inhibitors
EP1140903B1 (de) Aromatische amiden
AU764367B2 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)
EP2079694B1 (de) N-substituierte heterocycloalkyloxybenzamidverbindungen und verfahren zu ihrer verwendung
CZ374096A3 (cs) Matricové metalloproteasové inhibitory
US6130220A (en) Sulfamide-metalloprotease inhibitors
EP1192132A2 (de) Inhibitoren von serin proteasen
JP2012530757A (ja) 新規化合物、医薬組成物及びそれに関する方法
JP2006502980A (ja) アリールスルホニルヒドロキサム酸およびアミド誘導体、ならびにプロテアーゼ阻害薬としてのそれらの使用
CZ255199A3 (cs) Derivát sulfamidu inhibující metaloproteázu, způsob jeho přípravy a jeho použití pro výrobu léčiv
US7718679B2 (en) Heteroaryl carboxamides
DE4312966A1 (de) Neue 4-Aminopyridine - Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
CZ2001687A3 (cs) Arylpiperaziny a jejich použití jako činidel inhibujících metaloproteinázu (MMP)
AU2003262101A1 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)